Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Bicycle Therapeutics (BCYC) EBITDA (2018 - 2025)

Bicycle Therapeutics' EBITDA history spans 8 years, with the latest figure at -$20.2 million for Q4 2025.

  • For Q4 2025, EBITDA rose 58.42% year-over-year to -$20.2 million; the TTM value through Dec 2025 reached -$222.6 million, down 32.8%, while the annual FY2025 figure was -$222.6 million, 32.8% down from the prior year.
  • EBITDA reached -$20.2 million in Q4 2025 per BCYC's latest filing, up from -$59.2 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$14.4 million in Q3 2021 to a low of -$80.9 million in Q2 2025.
  • Average EBITDA over 5 years is -$37.4 million, with a median of -$34.7 million recorded in 2022.
  • The largest YoY upside for EBITDA was 58.42% in 2025 against a maximum downside of 139.41% in 2025.
  • A 5-year view of EBITDA shows it stood at -$18.2 million in 2021, then plummeted by 65.2% to -$30.1 million in 2022, then tumbled by 76.92% to -$53.3 million in 2023, then grew by 8.89% to -$48.6 million in 2024, then surged by 58.42% to -$20.2 million in 2025.
  • Per Business Quant, the three most recent readings for BCYC's EBITDA are -$20.2 million (Q4 2025), -$59.2 million (Q3 2025), and -$80.9 million (Q2 2025).